Sign in

Madeline

Research Analyst at William Blair

Madeline Welch is an Analyst who began her career as an investment banking intern at William Blair and BMO, focusing on a broad range of financial sectors. Although her current analyst role is at Slate Asset Management, she gained foundational experience at William Blair, contributing to projects for notable clients in investment banking. Madeline holds a Bachelor of Science in Finance from the Kelley School of Business at Indiana University and started her analyst position at Slate in 2024 as part of their Analyst Rotation Program. While still early in her career, she is building her credentials and experience across leading financial institutions, with professional licensing and performance data yet to be established.

Madeline's questions to Autolus Therapeutics (AUTL) leadership

Question · Q3 2025

Madeline, on behalf of Matt Pips, asked for rough timelines for completing the pivotal cohort in pediatric ALL and the total market opportunity across both adult and pediatric ALL patients.

Answer

Dr. Christian Itin, CEO of Autolus Therapeutics, estimated the pediatric ALL market opportunity in the US and Europe to be around 1,000 patients, with a significant proportion in the high-risk category. He projected that the phase two portion of the pediatric study could enter the follow-up period in 2027, with data potentially available in late 2027 or early 2028.

Ask follow-up questions

Fintool

Fintool can predict Autolus Therapeutics logo AUTL's earnings beat/miss a week before the call

Let Fintool AI Agent track Madeline for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free